Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
4 hedge funds and large institutions have $6.76K invested in Protagenic Therapeutics Warrant in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
157% more capital invested
Capital invested by funds: $2.63K → $6.76K (+$4.13K)
3.37% less ownership
Funds ownership: 7.67% → 4.3% (-3.4%)
33% less funds holding
Funds holding: 6 → 4 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$406 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$1.28K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$895 |
| 3 |
GS
GTS Securities
New York
|
-$202 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$21 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $4.77K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1.45K | -$895 | -24,806 | -49% |
|
|
TSS
3
Two Sigma Securities
New York
| $536 | +$406 | +11,242 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $5 | +$4 | +100 | New |
|
|
WAM
5
Warberg Asset Management
Winnetka,
Illinois
| – | -$1.28K | -170,242 | Closed |
|
|
GS
6
GTS Securities
New York
| – | -$202 | -25,300 | Closed |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$21 | -3,000 | Closed |
|
PTIXW Hedge Fund Activity: Q2 2025 in Review
4 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q2 2025, worth a combined $6.76K — up 157% from $2.63K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PTIXW and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $406. The largest seller was Warberg Asset Management, exiting entirely with an estimated $1.28K sold.
- 4 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q2 2025, down from 6 in Q1 2025.
- Funds reported $6.76K of Protagenic Therapeutics Warrant stock for Q2 2025, up 157% quarter-over-quarter.
- 2 funds opened new Protagenic Therapeutics Warrant positions in Q2 2025 and 4 closed out, a net change of -2 holders.
- The largest Protagenic Therapeutics Warrant buyer in Q2 2025 was Two Sigma Securities, an estimated $406 added.
- The largest Protagenic Therapeutics Warrant seller in Q2 2025 was Warberg Asset Management, an estimated $1.28K sold.
Based on aggregated 13F filings for Q2 2025.